Skip to main content

Table 4 Multivariate logistic regression of dependent variable cancer versus any TZD therapy (Rosiglitazone or Pioglitazone) and potential confounders stratified by gender

From: Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

Women (N = 535)

Ā Ā Ā 
Ā 

Odds ratio

P

95% CI

TZD therapy

2.07

0.01

1.18ā€“3.63

Age

1.02

0.25

0.99ā€“1.04

Biguanide use

1.63

0.09

0.93ā€“2.84

Sulfonylurea use

0.49

0.02

0.27ā€“0.89

Glycosolated hemoglobin A1C, %

0.94

0.59

0.76ā€“1.17

Body mass index, kg/m2

0.97

0.07

0.93ā€“1.00

Cigarette smoking

0.43

0.06

0.18ā€“1.03

High comorbidity conditions

2.90

0.001

1.56ā€“5.41

Number of prescription medications

1.09

0.03

1.01ā€“1.18

Men (N = 448)

Ā Ā Ā 

TZD therapy

1.20

0.63

0.58ā€“2.46

Age

1.05

0.01

1.01ā€“1.08

Biguanide use

0.99

0.97

0.51ā€“1.91

Sulfonylurea use

1.22

0.56

0.63ā€“2.35

Glycosolated hemoglobin A1C, %

0.83

0.22

0.62ā€“1.12

Body mass index, kg/m2

0.97

0.32

0.91ā€“1.03

Cigarette smoking

0.78

0.62

0.30ā€“2.03

High comorbidity conditions

4.29

<0.001

2.11ā€“8.72

Number of prescription medications

0.89

0.018

0.80ā€“0.98

  1. TZD, thiazolidinedione.